ClinicalTrials.gg
CompletedNCT04975334Updated Jun 3, 2026Results posted

Opioid Antagonism in Hypogonadotropic Hypogonadism

A Phase 1 interventional study of Naloxone in Hypogonadotropic Hypogonadism and Low Testosterone, sponsored by Stephanie B. Seminara, MD. Completed at 1 site in United States. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Stephanie B. Seminara, MD · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.

Enrollment
109th of 154
23 · median 45
Started
2025
with 4 others
Phase 1
29 of 185
none open now
Registered
169th of 185
by date
Lead sponsor
6 of 185
Stephanie B. Seminara, MD

Among the 185 studies in Hypogonadism with a site in United States, this one is the 109th largest by enrollment of the 154 interventional ones that give a count, is one of 5 that started in 2025, is one of 29 in phase 1, and was the 169th registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Hypogonadism with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with hypogonadotropic hypogonadism (HH).

Read the detailed description

Assignment: Each study subject will serve as their own control.

Delivery of Interventions:

  • Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories.
  • During the study, the subjects will undergo the following:

    • Undergo q10 min blood sampling for 3 hours
    • Receive a naloxone bolus at the midpoint of q10 min sampling
03

Conditions studied

  • Hypogonadotropic Hypogonadism
  • Low Testosterone

Browse trials for

Keywords

  • Hypogonadotropic Hypogonadism
  • naloxone
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • Age 18-75 years
  • Confirmed diagnosis of hypogonadotropic hypogonadism (low testosterone)
  • All medical conditions stable
  • Normal blood pressure (systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg)
  • Negative urine drug screening panel
  • Men on adequate testosterone replacement therapy: normal male reference range
  • Men off testosterone replacement therapy: no lower than 0.5 gm/dL below the lower limit of the reference range for normal women

Exclusion criteria

Exclusion

  • Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol
  • Current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis and, if applicable, unwilling to complete an appropriate for that particular medication and its method of administration
  • Current or recent use of a medication that affects the opioid pathway
  • Active illicit drug use
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    naloxone

    one period of frequent blood sampling with IV administration of naloxone (one bolus)

    Drug: Naloxone

Interventions

06

What researchers measure

Primary outcomes

  1. Average Change in Mean Luteinizing Hormone (LH) Value

    Change in mean LH before vs. after naloxone bolus

    Time frame: Before and after treatment, a 3 hour period on a single study day

07

Results

Posted May 1, 2026

Participant flow

Boston area. 23 participants were consented and screened for eligibility between 6/2025 and 8/2025.

Participant flow — Overall Study
MilestoneNaloxone
Started9
Completed9
Not completed0

Outcome measures

PrimaryAverage Change in Mean Luteinizing Hormone (LH) Value

Change in mean LH before vs. after naloxone bolus

Time frame:
Before and after treatment, a 3 hour period on a single study day
Reported as:
Mean · IU/L
Average Change in Mean Luteinizing Hormone (LH) Value
IU/LNaloxone
Average Change in Mean Luteinizing Hormone (LH) Value1.571 ± 2.714

Adverse events

Collected over From time of study consent until removal from study participation (approximately 5 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naloxone0/9 (0%)0/9 (0%)0/9 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Naloxone
<=18 years0
Between 18 and 65 years5
>=65 years4
Sex: Female, Male
Sex: Female, Male(Participants)Naloxone
Female0
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Naloxone
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White8
More than one race1
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Naloxone
Hispanic or Latino0
Not Hispanic or Latino9
Unknown or Not Reported0
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Sep 2025, 3 months.

Results were first posted in May 2026, 7 months after primary completion.

Of 13 phase 1 interventional studies under Hypogonadism, half reached primary completion within 32 months of starting (the median); a quarter within 18 and three quarters within 57. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2021
First posted
Jul 23, 2021
StartActual
Jun 18, 2025
Primary completionActual
Sep 26, 2025
CompletionActual
Sep 26, 2025
Results first posted
May 1, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04975334
Lead sponsor
Stephanie B. Seminara, MD
Responsible party
Stephanie B. Seminara, MD (Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine, Massachusetts General Hospital) — Sponsor-investigator
First posted
Jul 23, 2021
Start date
Jun 18, 2025
Primary completion
Sep 26, 2025
Completion
Sep 26, 2025
Results posted
May 1, 2026
Last update
Jun 3, 2026

Study contacts

Stephanie Seminara, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naloxone

Start the discussion